Previous close | 148.50 |
Open | 144.58 |
Bid | 139.20 x N/A |
Ask | 149.60 x N/A |
Day's range | 144.58 - 145.00 |
52-week range | 143.14 - 175.85 |
Volume | |
Avg. volume | 23,963 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 17 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
J&J will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates, discovered and engineered using its proprietary MATCH™ technology platform HORGEN, Switzerland, May 28, 2024 (GLOBE NEWSWIRE) -- Numab Therapeutics AG (Nu
NEW BRUNSWICK, N.J., May 28, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement with Numab Therapeutics, a clinical-stage biotechnology company advancing a pipeline of immunology and oncology therapeutics, to acquire from Numab's shareholders its wholly-owned subsidiary for the global rights to a novel, investigational first-in-class bispecific antibody, NM26, in an all-cash transaction of approximately $1.25 billion.
The fact that multiple Johnson & Johnson ( NYSE:JNJ ) insiders offloaded a considerable amount of shares over the past...